Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02181413 · ClinicalTrials.gov registry record · Phase 3
A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant
A Phase 3 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 3
- Development phase
- 656
- Enrollment target
NCT02181413 is a Phase 3 study that has completed, run by Takeda. The registered enrollment target is 656 participants.
The verdict
NCT02181413, a Phase 3 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 656 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effect of ixazomib citrate maintenance therapy on progression-free survival (PFS), compared to placebo, in participants with newly diagnosed multiple myeloma (NDMM) who have had a response (complete response \[CR\], very good partial response \[VGPR\], or partial response \[PR\]) to induction therapy followed by high-dose therapy (HDT) and autologous stem cell transplant (ASCT).
Interventions
- DRUG Placebo
- DRUG Ixazomib Citrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 656 participants |
| Start Date | 2014-07-16 |
| Est. Completion | 2023-09-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02181413
The ClinicalTrials.gov registry entry for NCT02181413 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 656 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02181413 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02181413 about?
NCT02181413 is a clinical study titled "A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant". The purpose of this study is to determine the effect of ixazomib citrate maintenance therapy on progression-free survival (PFS), compared to placebo, in participants with newly diagnosed multiple myeloma (NDMM) who have had a response (complete response \[CR\], very good partial response \[VGPR\], o...
What is the current status of trial NCT02181413?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 656 participants. The study started on 2014-07-16. Estimated completion is 2023-09-08.
What interventions are being tested in trial NCT02181413?
The interventions under investigation include: Placebo (DRUG), Ixazomib Citrate (DRUG).
Who is sponsoring clinical trial NCT02181413?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.